JP2017530127A - 心室性不整脈の予防、治療、又は遅延におけるニューレグリンの使用、及びその組成物 - Google Patents

心室性不整脈の予防、治療、又は遅延におけるニューレグリンの使用、及びその組成物 Download PDF

Info

Publication number
JP2017530127A
JP2017530127A JP2017516166A JP2017516166A JP2017530127A JP 2017530127 A JP2017530127 A JP 2017530127A JP 2017516166 A JP2017516166 A JP 2017516166A JP 2017516166 A JP2017516166 A JP 2017516166A JP 2017530127 A JP2017530127 A JP 2017530127A
Authority
JP
Japan
Prior art keywords
ventricular
nrg
arrhythmia
neuregulin
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017516166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530127A5 (https=
Inventor
ズホウ ミングドング
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55580273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017530127(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．, ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Publication of JP2017530127A publication Critical patent/JP2017530127A/ja
Publication of JP2017530127A5 publication Critical patent/JP2017530127A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2017516166A 2014-09-24 2015-09-06 心室性不整脈の予防、治療、又は遅延におけるニューレグリンの使用、及びその組成物 Pending JP2017530127A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410529437.4A CN105497876B (zh) 2014-09-24 2014-09-24 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN201410529437.4 2014-09-24
PCT/CN2015/088972 WO2016045493A1 (zh) 2014-09-24 2015-09-06 神经调节蛋白预防、治疗或延迟室性心律失常的用途及其组合物

Publications (2)

Publication Number Publication Date
JP2017530127A true JP2017530127A (ja) 2017-10-12
JP2017530127A5 JP2017530127A5 (https=) 2018-09-27

Family

ID=55580273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516166A Pending JP2017530127A (ja) 2014-09-24 2015-09-06 心室性不整脈の予防、治療、又は遅延におけるニューレグリンの使用、及びその組成物

Country Status (9)

Country Link
US (1) US10441633B2 (https=)
EP (1) EP3199174B1 (https=)
JP (1) JP2017530127A (https=)
KR (1) KR20170055492A (https=)
CN (2) CN105497876B (https=)
AU (1) AU2015320230B2 (https=)
CA (1) CA2961813A1 (https=)
RU (1) RU2017113775A (https=)
WO (1) WO2016045493A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US10894815B2 (en) 2012-10-08 2021-01-19 Zensun (Shanghai) Science & Technology, Co., Ltd. Compositions and methods for treating heart failure in diabetic patients
RU2015154737A (ru) 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3836913A4 (en) * 2018-08-14 2022-05-18 Emory University Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
AU2020348436A1 (en) * 2019-09-16 2022-04-07 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2001519400A (ja) 1997-10-14 2001-10-23 ケンブリッジ ニューロサイエンス インク． ニューレグリン使用を含む治療法
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
BRPI0606484A2 (pt) 2005-01-20 2009-06-30 Janssen Pharmaceutica Nv métodos para controle do intervalo qt
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CN101310766B (zh) * 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US8603817B2 (en) * 2008-11-03 2013-12-10 University Of Washington Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling
JP2012509908A (ja) 2008-11-28 2012-04-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
EP3087998B1 (en) 2009-06-09 2019-09-04 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin based methods for treating heart failure
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US20120028992A1 (en) * 2010-08-02 2012-02-02 Brown Arthur M Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
WO2012054718A2 (en) 2010-10-22 2012-04-26 The General Hospital Corporation Treating long qt syndrome
CN102302552A (zh) * 2011-08-31 2012-01-04 朱明军 一种治疗心律失常的胶囊及其制备方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US10894815B2 (en) 2012-10-08 2021-01-19 Zensun (Shanghai) Science & Technology, Co., Ltd. Compositions and methods for treating heart failure in diabetic patients
RU2015154737A (ru) 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
KR20160035061A (ko) 2013-08-01 2016-03-30 길리애드 사이언시즈, 인코포레이티드 긴 qt 증후군을 치료하기 위한 화합물 및 방법
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAWYER, D.B. ET AL., CIRCULATION, vol. 105, JPN6019022007, 2002, pages 1551 - 4, ISSN: 0004053920 *

Also Published As

Publication number Publication date
EP3199174A4 (en) 2018-06-06
EP3199174A1 (en) 2017-08-02
WO2016045493A1 (zh) 2016-03-31
US10441633B2 (en) 2019-10-15
CN105497876B (zh) 2021-01-15
AU2015320230A1 (en) 2017-03-30
US20170368140A1 (en) 2017-12-28
AU2015320230B2 (en) 2021-06-24
CA2961813A1 (en) 2016-03-31
KR20170055492A (ko) 2017-05-19
CN105497876A (zh) 2016-04-20
EP3199174B1 (en) 2022-04-13
RU2017113775A (ru) 2018-10-26
CN110337304A (zh) 2019-10-15
RU2017113775A3 (https=) 2019-04-04

Similar Documents

Publication Publication Date Title
JP7761964B2 (ja) 心不全の治療用組成物
JP2017530127A (ja) 心室性不整脈の予防、治療、又は遅延におけるニューレグリンの使用、及びその組成物
AU2021258063B2 (en) Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
US9089524B2 (en) Neuregulin based methods for treating heart failure
JP2019194208A (ja) 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
EP2440236B1 (en) Neuregulin based methods for treating heart failure
US11246909B2 (en) Neuregulin based methods for treating heart failure
CN102159236A (zh) 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
US20230083149A1 (en) Method for preventing, treating or delaying heart failure by using neuregulin, and composition
HK1241737A1 (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
HK1241737B (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200121